Therapeutic monoclonal antibodies (mAbs) exhibit significant interindividual pharmacokinetic (PK) variability, necessitating therapeutic drug monitoring (TDM). However, current monitoring methods require complex and time-consuming laboratory analysis, making r... ...

请注册登录后继续浏览